Personalized medicine: consequences for drug research and therapy

Thorsten Ruppert, Sabine Sydow, Günter Stock

Abstract

In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases. Medicine and drug development have seen a paradigm shift which can be characterized with the catchword “personalized medicine”, also called “stratified medicine” or “precision medicine”. Personalized medicine is based on defined tandems of therapeutic agents and diagnostic tests. With this addition to the regular medical examination of the patient, specific patient characteristics are determined. The results of such diagnostic tests are then decisive for the choice of therapy or control of the effectiveness of the chosen treatment. The benefit of personalized medicine for the patient is the higher probability of treatment success as well as improved effectiveness and reduced / avoided side effects. Health insurance systems and the public may have the advantage that the health funds can be used more efficiently on this basis. This new paradigm requires also a new debate on the remuneration in health care. In order to bring personalized therapies to patients as quickly as possible, all players in health care should work together to address the challenges associated with personalized medicine.

Keywords

personalized medicine; stratification of patient groups; tandems of therapeutic agents and diagnostic tests; patient care; cost efficiency

Full Text:

PDF

References

Federal Ministry of Education and Research, accessed July 18, 2016.

Stratifizierte medizin — der wegvom biomarker zum Kli-nikbettistweit, 2013, ÄrzteZeitung, accessed July 18, 2016.

Präzisionsmedizin auf dem Vormarsch, 2012, Springer- Verlag GmbH, accessed July 18, 2016.

von Holleben M, Pani M and Heinemann A, 2011, Medizinische Biotechnologie in Deutschland 2011 – Biopharmazeutika: Wirtschaftsdaten und Nutzen der Personalisierten Medizin, The Boston Consulting Group.

Stock G and Sydow S, 2013, Personalisierte medizin: paradigmenwechsel in der arzneimittelforschung und –therapie. Bundesgesundheitsblatt, vol.56: 1495–1501.

Association of Research-Based Pharmaceutical Companies, 2015, Forschungfür das leben: entwicklungsprojekte

für innovative arzneimittel, accessed July 18, 2016.

Fern Barkalow, 2014, Recent trends in personalized medicine: increasing clinical use and impact of pharmacogenetic and epigenetic biomarkers in Oncology, Citeline, accessed September 21, 2016.

Website of the German National Cohort, accessed June 12, 2016.

Association of Research-Based Pharmaceutical Companies, 2016, Drugs for personalized medicine approved in Germany, accessed June 12, 2016.

Standardized doctors' fee schedule (EBM) for use from July 1, 2016, accessed July 18, 2016.

Report on the results of the German Federal Government’s Pharma Dialog, accessed July 18, 2016.

Association of Research-Based Pharmaceutical Companies, 2015, vfa-Positionspapier “Personalisierte Medizin”, accessed July 18, 2016.


DOI: http://dx.doi.org/10.18063/APM.2016.02.004
(241 Abstract Views, 135 PDF Downloads)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Thorsten Ruppert, Sabine Sydow, Günter Stock

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

                                          

Advances in Precision Medicine is a peer-reviewed, open-access journal. All journal content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.